AZoLifeSciences on MSN2d
Uncovering Key Differences Between Humans and Mice in Cancer Immunotherapy Targets
Programmed cell death protein 1,” or PD-1, has been considered a key target in cancer therapies since its discovery in the ...
Scientists unveil surprising human vs. mouse differences in a major cancer immunotherapy target
Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer ...
C&EN2d
Flawed assumptions could be spoiling cancer immunotherapy research
Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...
Breakthrough Discovery Reveals Hidden Flaws in Cancer Research Models
Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...
Business Wire12d
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...